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Retinopathy of prematurity (ROP) is a neurovascular complication in preterm babies, 
leading to severe visual impairment, but the underlying mechanisms are yet unclear. 
The present study aimed at unraveling the molecular mechanisms underlying the patho-
genesis of ROP. A comprehensive screening of candidate genes in preterms with ROP 
(n = 189) and no-ROP (n = 167) was undertaken to identify variants conferring disease 
susceptibility. Allele and genotype frequencies, linkage disequilibrium and haplotypes 
were analyzed to identify the ROP-associated variants. Variants in CFH (p = 2.94 × 10−7), 
CFB (p = 1.71 × 10−5), FBLN5 (p = 9.2 × 10−4), CETP (p = 2.99 × 10−5), and CXCR4 
(p = 1.32 × 10−8) genes exhibited significant associations with ROP. Further, a quantita-
tive assessment of 27 candidate proteins and cytokines in the vitreous and tear samples 
of babies with severe ROP (n = 30) and congenital cataract (n = 30) was undertaken 
by multiplex bead arrays and further validated by western blotting and zymography. 
Significant elevation and activation of MMP9 (p = 0.038), CFH (p = 2.24 × 10−5), C3 
(p = 0.05), C4 (p = 0.001), IL-1ra (p = 0.0019), vascular endothelial growth factor (VEGF) 
(p = 0.0027), and G-CSF (p = 0.0099) proteins were observed in the vitreous of ROP 
babies suggesting an increased inflammation under hypoxic condition. Along with inflam-
matory markers, activated macrophage/microglia were also detected in the vitreous of 
ROP babies that secreted complement component C3, VEGF, IL-1ra, and MMP-9 under 
hypoxic stress in a cell culture model. Increased expression of the inflammatory markers 
like the IL-1ra (p = 0.014), MMP2 (p = 0.0085), and MMP-9 (p = 0.03) in the tears of 
babies at different stages of ROP further demonstrated their potential role in disease 
progression. Based on these findings, we conclude that increased complement activa-
tion in the retina/vitreous in turn activated microglia leading to increased inflammation. A 
quantitative assessment of inflammatory markers in tears could help in early prediction of 
ROP progression and facilitate effective management of the disease, thereby preventing 
visual impairment.
Keywords: retina, premature birth, inflammation, genetics, cytokines, abnormal angiogenesis, microglia/
macrophage, alternative complement pathway
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inTrODUcTiOn
Retinopathy of prematurity (ROP) is a complex disease of the 
retina with a multi-factorial etiology and an early intervention 
has been observed to prevent irreversible vision loss in some of 
these prematurely born infants (1). Its incidence in developed 
countries with adequate neonatological facilities (like United 
States) is 19.88% (2) while it is slightly higher (~30%) for middle-
income developing countries (3, 4). In India, approx. two million 
babies are at risk of developing ROP annually (4) with an overall 
incidence estimated to be around 45% (5, 6). Hence, ROP is one of 
the major causes of visual impairment in India. Lower gestational 
age (GA), lower birth weight (BW), and oxygen supplementation 
are the primary risk factors associated with ROP (7). It is a self-
limiting disease with initial symptoms of avascular retina that 
progresses to abnormal growth of retinal vessels causing retinal 
detachment (8). Hypoxia in the avascular retina is considered to 
be the primary cause for neovascularization in ROP that further 
activates various cellular pathways such as HIF1α, eNOS/iNOS, 
and vascular endothelial growth factor (VEGF) signaling leading 
to abnormal neovascularization (9, 10). However, the detailed 
molecular mechanisms underlying neovascularization in ROP 
have not been elucidated yet. So far, few functionally relevant 
genes (NDP, FZD4, LRP5, CFH, VEGF, ANGPT2, EPO, BDNF, 
and CETP) have been associated with ROP in a small fraction of 
cases. But, many of these variants could not be replicated across 
different ethnicities (11–13). Further, their roles in risk predic-
tions and disease management are yet to be determined.
The protein profiles in the vitreous have been utilized for 
studying the underlying pathology of the retina due to its proxim-
ity. This has largely been accomplished by analyzing the levels 
of erythropoietin, VEGF, and cytokines like interleukins (IL-6, 
IL-7, IL-10, and IL-15), Eotaxin, FGF basic, G-CSF, GM-CSF, 
IP-10, and RANTES in the vitreous to identify their potential as 
biomarkers for ROP progression (14–16). Interestingly, interleu-
kin-7 (IL-7), monocyte chemotactic protein-1, and macrophage 
inflammatory protein 1 (MIP-1α and MIP-1β) levels were also 
found to be significantly elevated in the cord blood serum of ROP 
(17). Earlier, low serum levels of IGF-1 and VEGF were reported 
in preterm babies with severe ROP and low GA (18, 19). Thus, 
the studies on protein profiling and genetic associations of ROP 
could explain the susceptibility of some preterm babies progress-
ing to severe ROP.
Our study is an attempt to comprehensively elucidate the genomic 
basis of ROP and identify the potential biomarkers for progression 
to severe stages. Since, no mutations were observed in the Norrin 
signaling genes in ROP in our earlier study (20), we explored genes 
involved in angiogenesis, growth, and development of the fetal 
retina, trans-endothelial migration, oxidative stress, inflammation, 
and neurodegenerative processes, in order to understand their role 
in ROP pathogenesis. We observed strong associations of ROP 
with the variants in CFH, CFB, CXCR4, FBLN5, and CETP genes 
along with increased levels of proteins in the extracellular matrix 
(ECM) and complement pathways in the vitreous of these babies. 
We observed the presence of the activated microglia/macrophages 
in the retina and vitreous. We further demonstrated the activated 
microglial cells under hypoxia expressed complement C3, VEGF, 
and IL-1β, thereby resulting in abnormal blood vessel proliferation 
in the ROP-affected eyes. We also evaluated the inflammatory pro-
teins as potential biomarkers for ROP based on their expressions in 
the tear samples of the ROP patients.
MaTerials anD MeThODs
study subjects
The study protocol adhered to the tenets of declaration of Helsinki 
and was approved by the Institutional Review Board (LEC02-
14-029) of the L V Prasad Eye Institute (LVPEI). Preterm babies 
referred for further management from the neonatal intensive care 
units of different hospitals in Hyderabad to the LVPEI between 
January 2007 and December 2010 were enrolled. Overall, the 
study cohort comprised 372 preterm babies of GA ≤  35 weeks 
and/or BW ≤ 1,700 g with ROP (n = 189) and no-ROP (n = 167). 
A detailed demographic and clinical history (Table S1 in 
Supplementary Material) of all the preterm babies enrolled were 
documented and a written informed consent was obtained from 
their parents. The diagnosis and categorization of ROP cases from 
mild to severe form was based on severity (stages 1–5), location 
(zones I, II, III), amount of disease (clock hours), and presence 
or absence of “plus” disease following ICROP guidelines (20, 21) 
(Figure S2 in Supplementary Material). Severe ROP includes 
progressive disease, which requires prompt treatment. It includes 
any stage (1–5) Zone I with plus and stages 2–3 Zone II with 
plus. Mild ROP cases include less severe disease, which does not 
require any treatment. Although until the regression of the disease 
completely, babies are under regular follow-up for ROP screening.
sample collection
Venous blood (0.5–1 mL) was collected from the ROP and no-
ROP preterm babies by venipuncture. DNA was extracted from 
the blood samples using an automated DNA extraction platform 
(MagNa Pure LC 20, Roche) following the manufacturers guide-
lines. Likewise, for proteomic studies, the vitreous humor samples 
(100–500 µL) were collected from preterm babies with stage IV 
and V ROP (n = 30) who had undergone vitrectomy as a part of 
their routine clinical management. The controls for the proteomic 
studies included babies with congenital cataract (<6 months of 
age) who underwent partial vitrectomy as part of the surgical 
management (n = 30). The vitreous samples were immediately 
centrifuged at relative centrifugal force (rcf) of 10,621 g and the 
supernatant was stored at −80°C deep freezer until further use.
Additionally, crude tears were collected before instilling any 
drops or drug for pupil dilation in the eyes of preterm babies with 
ROP (Stage II–V) (n = 27) and no-ROP (n = 13) using a capillary 
tube and without touching the conjunctiva. The tear samples for 
ROP subjects were collected during the active disease condition 
either before or after 3 months following medical intervention.
customized genotyping of  
candidate Variants
A customized panel containing 384 single-nucleotide polymor-
phisms (SNPs) from 26 chosen genes (Table S2 in Supplementary 
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Material) involved in growth and development of the fetal retina, 
angiogenesis, inflammation, neurodegeneration, and oxidative 
stress processes were genotyped using a microarray platform 
(Illumina Inc., golden gate assay). Following hybridization, the 
fluorescent signals were scanned by a bead array reader and 
the raw signal intensities were imported to the Genome Studio 
software (version 1.9) for assessing quality scores. The assay 
and sample reliability were measured by means of the gen call 
score and the genotypes were called following clustering. The 
genotypes of a subset of samples for all the genes were validated 
by resequencing on an automated DNA sequencer (ABI 3130 XL) 
using the BigDye chemistry.
Quantitative assessment of cytokines and 
Other Proteins in the Vitreous and Tear 
samples
The concentrations of 27 cytokines (Bio-Plex Human cytokine 
27-Plex, Bio-Rad, Hercules, CA, USA) and 28 different proteins 
(HMMP1-55K, HMMP2-55K, HNDG1-36K, HNDG2-36K, 
HTIMP2-54K, TGFB-64K-03, HYCYTOMAG-60K, Merck 
Millipore, Billerica, MA, USA) involved in ECM remodeling, 
angiogenesis and inflammatory pathways were screened by 
multiplex bead immunoassays using the Luminex xMAP tech-
nology in vitreous samples that were pre-diluted to concentration 
1:3. Similar assay was used for estimating the concentrations of 
MMPs and cytokines in the tears samples and were quantitated by 
comparing them with their respective standard curve. All stand-
ards and some of the samples (due to less volume of samples) were 
measured in duplicates.
Validation of the Differentially regulated 
Proteins by Western Blotting and 
Zymography
A part of vitreous sample (50–100 µL) was lysed using a buffer 
containing 50 mM Tris-HCl (pH = 8), 120 mM NaCl, 0.5% NP40, 
protease inhibitor cocktail, and precipitated with acetone. The 
protein pellet was eluted in 50 µL of 1× phosphate buffered saline 
(PBS) containing the protease inhibitor cocktail and quantified 
by bicinchoninic acid assay. The normalized vitreous proteins 
(10 µg) were then subjected to western blotting. Western blotting 
was done using mouse anti-human C3 antibody (sc-28294, Santa 
Cruz) and mouse anti-human C5 (MAB2037, R&D Systems) 
followed by incubation with IRDye® 680RD secondary antibody. 
The entire procedure was done according to the manufacturer’s 
recommended application protocol (https://www.licor.com).
MMP gelatinase activity was measured in the vitreous and tear 
of ROP babies and controls by zymography as described earlier 
(22). An equal volume of crude vitreous and tear samples were 
electrophoresed under non-reducing conditions in 10% SDS-
PAGE gels polymerized with 1 mg/mL gelatin. The gel was washed 
with 2.5% Triton X-100 for 30 minutes at room temperature with 
gentle agitation, followed by rinsing with distilled water. The gel 
was then incubated for 30 min in developing buffer containing 
50 mM Tris-HCl, pH 7.8, 5 mM CaCl2, 0.2 M NaCl, 0.02% Brij 
35. The gel was incubated with fresh developing buffer at 37°C 
for 16 h and stained with Coomassie blue (Bio-Rad). This was 
followed by destaining with 10% v/v methanol, 5% v/v acetic 
acid in dH2O. Active MMP (MMP2/MMP9) band was detected 
in the zymogram in the discovery cohort. The observations of 
discovery cohort were further validated in tears in an extended 
cohort of patients at different stages of ROP: no-ROP (n =  9), 
mild ROP regressed (n = 6), mild ROP_progressed (n = 7), and 
severe ROP (n = 12) by zymography in order to confirm their role 
as biomarker in ROP pathogenesis. Zymogram band intensities 
were calculated with ImageJ software.
immunohistochemistry and hematoxylin 
and eosin (h&e) staining for Macrophage/
Microglia in the Vitreous
Vitreous were subjected to cytospin to separate the cells that 
were embedded in the parafilm block. Sections were cut, air 
dried, and stained with H&E (23) for understanding their mor-
phology. Tissue sections were then deparaffinized using xylene 
and gradually rehydrated with ethanol. Antigen retrieval was 
done by microwaving the sections at full power for 4–5 min in 
Tris EDTA buffer (10  mM Tris, 1  mM EDTA, 0.5% tween 20, 
pH 9.0). Blocking was carried out with 2.5% (w/v) BSA in PBS 
(10  mmol/L sodium phosphate, pH 7.5, 120  mmol/L sodium 
chloride) for 30 min at room temperature. Thereafter, the slides 
were incubated for 60 min with the primary antibody (CD 68 for 
human 1:100) diluted in 1× PBS, followed by three washings with 
PBS. Further incubation was carried out with biotinylated anti-
mouse immunoglobulin. Sections were then washed in PBS and 
incubated with avidin DH/biotinylated horseradish peroxidase 
reagent in PBS for 30 min before final washing. The antigen was 
localized using 1 mg/mL diaminobenzidene tetrahydrochloride 
(DAB; Sigma), 0.2% H2O2 in 50 mmol/L Tris–HCl, pH 7.6, which 
appeared as a brown end product. Sections were then counter-
stained with DAPI for nuclei staining.
response to hypoxia by the cultured 
Microglia cells
The human microglial cell line (CHME3) was cultured in 
DMEM containing 10% FBS along with antibiotics penicillin 
and streptomycin. The confluent cells were trypsinized using 
0.25% trypsin-EDTA. Hypoxic stress was introduced in the 
microglia cells by treating them with Cobalt chloride (CoCl2) 
at various concentrations from 100 to 250 µm. Briefly, around 
15,000 cells were seeded on a six well plate and then serum 
deprived for 6 h, followed by treatment with CoCl2 for 24 h on 
attaining 70–80% confluency. The serum deprived cells in the 
same duration that were not treated for hypoxia were used as 
controls.
ca2+ staining and live cell imaging
The cells were washed in HBSS (Thermoscientific, Waltham, 
MA, USA) and then incubated with the calcium binding dye 
Flu-4 (diluted with HBSS 1:750) for 30 min. After washing the 
cells with HBSS three times, live cell imaging was performed for 
10 min using an EVOS fluorescent microscope (Thermo Fischer 
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Scientific, Waltham, MA, USA) under 20× magnification. The 
cytosolic calcium flux was measured using the change in Fluo-4 
intensity over time for individual cells (Excitation: 494  nm 
Emission: 506 nm) (24).
semi-Quantitative Pcr
The RNA from untreated and treated cells was extracted by 
Trizol method (25). The cDNA was prepared using iScript cDNA 
synthesis kit (Bio-Rad, CA, USA). Semi quantitative PCR was 
carried out using the specific primers (Table S3 in Supplementary 
Material) for VEGF165, C3, HIF1α, BAX, and IL-1β while β-actin 
was used as an endogenous control.
statistical and Bioinformatic analysis
Allele frequencies of all the 384 variants were calculated by 
gene counting method along with odds ratio and 95% CI. 
A p value <  0.05 was considered to be significant. The associ-
ated allele and haplotype frequencies were further analyzed for 
statistical correction using Bonferroni and permutations tests 
(n = 10,000 permutations). Estimates of Hardy–Weinberg equi-
librium (p > 0.001), linkage disequilibrium (LD), and haplotype 
frequencies were calculated using the Haploview software (ver-
sion 4.2) (26).
Protein and cytokine levels in ROP and control samples were 
represented as bar plot (the mean ± SE) and box plot (median, 
interquartile range, and whiskers). Comparison of proteins and 
cytokines levels between ROP and controls vitreous/tears were 
calculated using the unpaired Student’s t-test. A p-value < 0.05 
was considered to be statistically significant. Since the cytosolic 
calcium level does not follow a normal distribution, we performed 
the testing of equality in medians for control and hypoxic condi-
tion using Wilcoxon rank-sum test.
resUlTs
involvement of genes in rOP
Of the 384 variants screened (Table S2 in Supplementary Material), 
73 were removed from further analysis as they were either not 
in Hardy-Weinberg equilibrium in the controls (n =  16), were 
monomorphic (n = 44), or had a call rate < 97% (n = 13). Thus, 
311 SNPs from 26 genes were finally analyzed for association with 
ROP. Among these 37 SNPs in 14 genes (AGTR1, ANGPT2, C3, 
CFH, CFB, CXCR4, FBLN5, H2AFX, IHH, MMP2, TGFβ1, CETP, 
VEGF, and TSPAN12) exhibited significant association (p < 0.05) 
with ROP (Table 1). Additionally, 5/37 associated SNPs in CFH, 
CFB, CXCR4, FBLN5, and CETP genes withstood Bonferroni cor-
rection. Intriguingly, only the CETP variant (rs891141) conferred 
significant risk of ROP, while the variants across the other genes 
were protective (Table 1). Strong LD was observed across all the 
variants (except rs1831821) in CFH and rs891141 and rs289716 in 
CETP gene, while moderate LD was observed between rs891141 
and rs289713 in CETP and rs2268002 and rs2284340 in FBLN5 
(Figure S1 in Supplementary Material).
Likewise, haplotypes generated with the associated and flank-
ing variants of these five genes revealed that only the haplotype 
C-A-T in CETP conferred significant risk of ROP, while those with 
CFH and FBLN5 were protective. Haplotypes with the CXCR4 
and CFB were not informative (Table 2). Thus, the present study 
highlights the potential involvement of novel genes (CFH, CFB, 
CETP, FBLN5, and CXCR4) in ROP based on their allelic and 
haplotype associations.
Quantitative assessment of Proteins 
involved in complement cascade and 
neurodegeneration in the Vitreous 
samples of rOP subjects
Based on strong associations in the CFH and CFB genes, a 
quantitative assessment of a neurodegenerative panel contain-
ing CRP, SAP, MIP-4, Complement C4, apolipoprotein AI, 
apolipoprotein CIII, apolipoprotein E, Complement Factor 
H, and Complement C3 proteins was carried out by multiplex 
immuno-bead assay in the vitreous samples of ROP patients 
(n =  30) and controls (n =  30). All the complement compo-
nents and apolipoproteins were detectable in the vitreous 
samples. Overall, we observed significantly elevated levels of 
C3 (p = 0.05), C4 (p = 0.001), CFH (p = 2.24 × 10−5), VEGF 
(p = 0.0027), apolipoprotein AI (p = 0.0007), and apolipopro-
tein CIII (p = 0.004) in the vitreous of ROP compared to the 
control subjects indicating their possible involvement in the 
disease pathogenesis (Figure 1A).
activation of complement Pathway in 
Vitreous humor of Proliferative rOP
We validated the differential expression of complement compo-
nent C3 by western blotting. An intense band of 192 kDa cor-
responding to C3 molecule was observed in ROP cases compared 
to controls (Figure 1B). Additionally, we observed the activated 
C3 fragments; C3b (182  kDa), C3c (145  kDa), and iC3bα 
(63 kDa) in the ROP vitreous under non-reducing conditions as 
confirmed by mass spectrometry (data not shown here), but not 
in the controls (Figure 1B), suggesting a higher activation of C3 
in ROP. Likewise, a higher expression of complement component 
C5 was observed in ROP vitreous compared to the controls (data 
not shown) suggesting a further activation of the complement 
pathway.
hypoxia-induced activated Macrophage 
secretes angiogenic Molecules
We further demonstrated that along with increased expression 
of angiogenic molecules in the vitreous samples of patients, 
activated macrophages/microglia in turn would also be 
secreting proinflammatory cytokines that might exacerbate 
the inflammation, further playing a role in the ROP pathogen-
esis. We detected activated macrophages/microglia on H&E, 
further confirmed by immunostaining with CD68 in ROP 
vitreous but not in the controls (Figure 1C). The results of this 
experiment supported for shift in the proangiogenic state as 
demonstrated by a significant increase in the levels of cytokines 
IL8 (p =  0.0149), G-CSF (p =  0.0099), IL1ra (p =  0.0019), 
TaBle 1 | Association of gene variants with retinopathy of prematurity (ROP).
genes 
screened
single-
nucleotide 
polymorphism 
(snP) iD
location nucleotide 
change
amino 
acid 
change
regulomeDB (binding score) (27) Minor 
allele
Minor allele 
frequencies
p-Value Odds ratio [95% ci]
rOP controls
CFH rs374896 intron g.71371T>C – Minimum binding evidence (6) T 0.0426 0.159 2.94 × 10−7 0.241 [0.135–0.431]
CFB rs1048709 exon g.19461A>G p.R150R Likely to affect binding of POLR2A and linked expression of the 
HLAC, HLA-DQA1, HLADQB1, HLADRB1, HLADRB5
g 0.15 0.269 1.71 × 10−5 0.484 [0.035–0.676]
C3 rs344550 Intron g.37710G>C – Likely to affect binding of GATA2, MYC, NR2F2, STAT5A, 
SPI1CCNT2 (1F)
C 0.223 0.29 0.0409 0.703 [0.501–0.986]
rs2287846 Intron g.24106G>C – Minimal binding evidence (5) G 0.298 0.237 0.0658 1.370 [0.979–1.915]
CXCR4 rs2228014 exon g.2652C>T p.I142I Minimum binding evidence (4) g 0.422 0.637 1.32 × 10−8 0.416 [0.307–0.565]
ANGPT2 rs2922889 Intron g.119194A>T – Minimum binding evidence (6) T 0.497 0.431 0.0776 1.305 [0.971–1.756]
rs2515464 Intron g.35092A>C – Minimum binding evidence (5) T 0.173 0.251 0.0102 0.622 [0.432–0.895]
rs734701 Intron g.32684C>T – Minimum binding evidence (6) A 0.452 0.527 0.0465 0.741 [0.551–0.996]
rs2959812 Intron g.29629T>C – Minimum binding evidence (5) C 0.471 0.548 0.0391 0.732 [0.544–0.985]
VEGF rs2010963 5′-UTR – – Minimum binding evidence (4) C 0.302 0.243 0.0084 1.352 [0.969–1.888]
rs1413711 Intron  g.2758T>C – Minimum binding evidence (4) T 0.39 0.482 0.014 0.688 [0.51–0.928]
rs1005230 Intergenic – – Minimum binding evidence (5) A 0.388 0.482 0.011 0.680 [0.505–0.917]
FBLN5 rs2268002 intron  g.17582G>C – Minimum binding evidence (5) g 0.32 0.423 9.2 × 10−4 0.641 [0.492–0.835]
MMP2 rs2285052 Intron g.88546A>C – Minimum binding evidence (5) G 0.092 0.036 0.0025 2.732 [1.39–5.368]
TGFb1 rs11466359 Intron  g.22217C>T – Minimum binding evidence (5) T 0.093 0.0482 0.021 2.027 [1.1–3.734]
rs4803457 Upstream g.4544T>C – Minimum binding evidence (4) A 0.465 0.536 0.061 0.754 [0.561–1.013]
CETP rs891141 intron g.7962G>T – Minimum binding evidence (5) c 0.234 0.114 2.99 × 10−5 2.378 [1.57–3.598]
H2AFX rs640603 Intergenic 3′ 
of a gene
– – Likely to affect binding of PLR2A, CHD1, E2F6, MXI1, E2F4, E2F6, 
MYC (2b)
T 0.161 0.09 0.0049 1.940 [1.215–3.085]
TSPAN12 rs41624 Intron g.62819A>G – Minimum binding evidence (6) T 0.176 0.243 0.0279 0.665 [0.462–0.958]
rs41629 Intron g.59568T>G – Minimum binding evidence (6) A 0.176 0.243 0.0279 0.665 [0.462–0.958]
rs3735467 Intron g.47721G>T – Minimum binding evidence (5) C 0.177 0.246 0.031 0.669 [0.465–0.964]
rs12669167 Intron g.38926T>G – NA (7) C 0.173 0.24 0.0279 0.664 [0.46–0.958]
rs10225453 Intron g.36511C>A – Minimum binding evidence (5) T 0.17 0.236 0.0287 0.663 [0.458–0.959]
rs6953454 Intron g.33908G>A – NA (7) T 0.172 0.237 0.03 0.666 [0.461–0.964]
rs996903 Intron g.32898A>G – Likely to affect binding and linked expression of the FLJ21986 (1F) C 0.17 0.237 0.0279 0.662 [0.458–1.044]
rs6959328 Intron g.32490T>A – NA (7) A 0.17 0.237 0.0279 0.662 [0.458–1.044]
rs6466759 Intron  g.28767A>T – Minimum binding evidence (5) T 0.17 0.238 0.0251 0.657 [0.454–0.95]
rs7805211 Intron g.25107G>A – Minimum binding evidence (6) A 0.168 0.237 0.0218 0.65 [0.449–0.941]
rs6466760 Intron g.24403C>G – Minimum binding evidence (6) C 0.168 0.237 0.0218 0.65 [0.449–0.941]
rs6466762 Intron g.16639G>A – Minimum binding evidence (5) A 0.169 0.241 0.0167 0.638 [0.441–0.923]
rs3823859 Intron – – Minimum binding evidence (5) G 0.17 0.24 0.0219 0.651 [0.451–0.941]
rs17142995 Intron g.11660A>G – Minimum binding evidence (6) C 0.173 0.24 0.0279 0.664 [0.46–0.958]
rs7781985 Intron g.6475A>C – Likely to affect binding and linked expression of the FLJ21986/
monocytes (1F)
C 0.17 0.24 0.0219 0.651 [0.451–0.941]
rs3757557 5′UTR g.91G>A – Minimum binding evidence (4) A 0.117 0.171 0.0411 0.644 [0.421–0.985]
rs4141309 Intergenic, 
upstream 5′ 
of gene
– – Minimum binding evidence (4) A 0.112 0.171 0.0236 0.611 [0.398–0.939]
AGTR1 rs2739504 Intron g.13100A>G – Minimum binding evidence (4) C 0.446 0.371 0.041 1.362 [1.012–1.833]
IHH rs394452 Exon g.5153T>C p.T376T Minimum binding evidence (5) T 0.261 0.168 0.0027 1.75 [1.211–2.528]
SNPs in bold withstood Bonferroni correction.
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FigUre 1 | Expression of inflammatory molecules in proliferative retinopathy of prematurity (ROP). (a) Differential levels of complement components and 
apolipoproteins in the vitreous humor of ROP and controls (B) Western blotting of C3 done under non-reducing condition, showing its expression in patients (lane 1 
and 2) and controls (lane 3 and 4). Arrows indicate the C3 fragments. Thin black line inserted within gel showing that all the lanes were run on the same gel but were 
not continuous (c) Hematoxylin and eosin staining of ROP vitreous. Arrowheads indicate degenerated morphology of macrophages at 40×-magnification (irregular 
shaped with large vacuole, nucleus with a very prominent nucleolus); Staining of ROP vitreous with CD68 marker. Arrowheads indicate the presence of activated 
macrophages at 10× magnification. (D) Differential levels of inflammatory cytokines in the vitreous humor of ROP and controls. Error bars in (a) and (D) show SEM, 
*p < 0.05, **p < 0.005, ***p < 0.0005 (ROP vs. controls).
TaBle 2 | Estimated haplotype frequencies of the significantly associated variants in CETP, CFH, and FBLN5 genes in retinopathy of prematurity (ROP) and premature 
controls.
genes (single-nucleotide 
polymorphisms)
haplotypes Overall 
frequencies
rOP 
frequencies
controls 
frequencies
chi square p-Value Odds ratios (95% ci)
CETP (rs891141, rs289713, rs289716) A-A-T 0.327 0.313 0.343 0.734 0.3916 0.871 (0.637–1.193)
A-A-A 0.3 0.294 0.308 0.156 0.6931 0.937 (0.68–1.292)
C-A-T 0.149 0.191 0.101 11.358 0.0008 2.1 (1.354–3.256)
A-T-A 0.143 0.121 0.169 3.357 0.0669 0.674 (0.442–1.029)
A-T-T 0.053 0.04 0.067 2.488 0.1147 0.586 (0.3–1.144)
CFH (rs3753395, rs374896, rs393955) T-C-T 0.563 0.578 0.547 0.693 0.4052 1.134 (0.843–1.526)
A-C-G 0.188 0.233 0.139 10.066 0.0015 1.874 (1.268–2.769)
A-C-T 0.151 0.149 0.154 0.032 0.8586 0.962 (0.638–1.451)
A-T-G 0.096 0.04 0.156 27.61 1.48 × 10−7 0.226 (0.125–0.41)
FBLN5 (rs2268002, rs2284340) G-C 0.38 0.413 0.343 3.621 0.0571 1.346 (0.992–1.826)
G-G 0.37 0.311 0.437 12.093 5 × 10−4 0.58 (0.427–0.789)
A-C 0.242 0.271 0.21 3.625 0.0569 1.4 (0.989–1.983)
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and VEGF (p = 0.0027) (Figures 1A,D) along with marginal 
increase of IL6, IL12, IL7, RANTES, and MCP1 in the ROP 
vitreous (data not shown).
To further confirm these results, we subjected the cultured 
microglial cells to hypoxic condition and checked for the expres-
sion of proinflammatory markers. The effect of hypoxia on the 
activation of macrophages/microglia was observed with an 
intense calcium staining in cells exposed to hypoxia compared 
to the unexposed ones. The result shows that there is increase 
in cytosolic calcium levels in case of hyperactivated cells sub-
jected to 24 h of hypoxic stress (Figure 2A, n = 50). Specifically, 
there is a significant increase (p < 0.0005) in cytosolic calcium 
FigUre 2 | Hypoxia induced microglia secretes inflammatory and angiogenic molecules. (a) Time lapse imaging of cytosolic calcium in microglial cells in normal 
and hypoxic conditions. Scale bar: 200 µm (B) Comparison of Camax (Maximum Fluo-4 intensity) in microglial cells for control and hypoxic condition [Ca2+transients 
were measured for 50 cells (n = 50) for each cases]. Data are presented as box plot and were analyzed using Wilcoxon rank-sum test. (c) Semi-quantitative PCR 
was used to evaluate the expression of secreted product (HIF-1α, IL-1β, BAX, C3, VEGF) of hypoxia-induced microglial cells treated with no CoCl2 (lane 1), 100 µM 
CoCl2 (lane 2), and 150 µM CoCl2 (lane 3) and β-actin as control.
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(Camax  =  the maximum Fluo-4 intensity) in microglial cells 
followed by hypoxia exposure (Figure 2B). Likewise, a higher 
expression of complement C3, VEGF165, and hypoxia induc-
ing factor-1α (HIF-1α) was also observed in exposed cells 
(Figure 2C).
involvement of extra-Matrix 
Metalloproteinases in Pathogenesis  
of rOP
A strong association of SNPs in FBLN5 and moderate association 
of MMP2, TGFβ gene (Table  1) with ROP suggested the role 
of ECM proteins in ROP pathogenesis. Further, a quantitative 
assessment of the ECM proteins indicated a significant increase 
in MMP9 (p = 0.038), TIMP1 (p = 0.004), and α2 macroglobulin 
(p = 0.0018) in the ROP vitreous (Figure 3A). We also assessed 
the MMP activation in ROP by gelatine zymography. Our results 
showed higher levels of both pro and activated MMPs (MMP9 
and/or MMP2) in the vitreous of patients suggesting its potential 
role in disease pathogenesis (Figure 3B).
exploring the Potential of inflammatory 
Markers in Tear samples for the 
Progression of rOP
We explored if increased expression of inflammatory markers 
(as seen in the vitreous samples of ROP patients) could also be 
reproducibly detected in tears and further be established as the 
biomarker for disease progression. A quick multiplex ELISA of 
tear samples collected from the ROP babies at different stages 
and no-ROP preterms was performed for some inflammatory 
markers (interleukins, TNFα, IFNγ, and MMPs). Significantly 
higher expressions of IL-1ra (p =  0.014), MMP2 (p =  0.0085), 
and MMP-9 (p = 0.03) were detected in severe ROP cases com-
pared to mild ROP and no-ROP tear samples that was further 
confirmed by zymography (Figures 3C–E). On the zymogram, 
the tear samples from no-ROP showed very low expression of 
MMPs as compared to severe ROP (Figure 3E). These results were 
confirmed to be reproducible in the extended cohort of ROP with 
a significant increased expression of activated MMP2 in severe 
ROP (p = 0.0023) and progressive ROP (p = 0.007) as compared 
FigUre 3 | Extracellular matrix (ECM) metalloproteinases and cytokines increases in proliferative retinopathy of prematurity (ROP) in both vitreous and tears 
samples. (a) Differential levels of ECM proteins and its inhibitors in ROP and control vitreous [*p < 0.05, **p < 0.005, *** p < 0.0005 (ROP vs. controls)].  
(B) Zymogram shows activation of MMPs in ROP vitreous (lanes 5, 6, 7, 8) as compared to controls (1, 2, 3, 4). (c) Differential levels of cytokines in ROP (5 µL)  
and control tears (5 µL). (D) Differential levels of MMPs in ROP (5 µL) and control tear (5 µL) [*p < 0.05, **p < 0.005, ***p < 0.0005 (severe ROP vs. mild 
ROP + premature controls)]. (e) Zymography showing more activation of MMPs in severe ROP (lanes 6, 7) as compared to mild ROP (lanes 4,5) and controls  
(5 µL tears; lanes 1, 2, 3). Error bars show SEM.
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to mild ROP (p = 0.01) and premature controls. Similar pattern of 
gradual increase in MMP9 expression was also observed in mild 
ROP (p = 0.02) to progressive (p = 0.001) and severe ROP cases 
(p = 1.2 × 10−6) with respect to premature controls (Figure 4).
DiscUssiOn
Retinopathy of prematurity is a biphasic disease that includes 
an initial phase of hyperoxia leading to blood vessel obliteration 
followed by hypoxia causing vessel proliferation eventually lead-
ing to neovascularization and neurodegeneration. It is a complex 
disease with multifactorial etiologies. An earlier study on 
monozygotic and dizygotic twin pairs had also noted the genetic 
involvement in the development of ROP, in absence of other envi-
ronmental factors (28). While supplemental oxygen is considered 
as a major risk factor along with lower GA and BW, studies from 
India and other Asian countries have reported ROP babies with 
higher GA and BW (29) and oxygen supplementation does not 
always predict the risk of ROP (6). Therefore, we hypothesized 
that genetic predisposition along with environmental/maternal 
or other risk factors may lead to the development of ROP.
A strong association of gene variants involved in the com-
plement pathway (CFH, CFB, C3), ECM remodeling (FBLN5, 
MMP9), leukocyte transendothelial migration and activation 
FigUre 4 | A role of MMPs in tears as biomarker for retinopathy of prematurity (ROP) progression: differential expression of Zymogram band intensities of (a) 
MMP9 and (B) MMP2 in extended cohort including severe ROP (n = 10), mild ROP_progressed (n = 6), mild ROP_regressed (n = 7), and no ROP premature 
controls (n = 9) [*p < 0.05, **p < 0.005, *** p < 0.0005 (ROP vs. controls)], AU, arbitrary unit.
TaBle 3 | Comparison of commonly associated gene variants in retinopathy of 
prematurity worldwide.
associated 
genes
associated 
single-nucleotide 
polymorphisms 
(associated allele)
Present 
study (india), 
a189/167
study by 
Mohamed 
et al. (11) 
(U.K.), 
a102/228 
study by 
hartnett 
et al. (13) 
(Usa), 
a593/364
CFH rs529825 (A) p = 0.7521 p = 0.01 –
rs800292 (A) p = 0.3186 p = 0.01 –
rs379489 (A) p = 0.4343 – p = 0.3926
rs395544 (A) p = 0.5525 – p = 0.403
CETP rs289747 (T) p = 0.5688 p = 0.004 –
GP1BA rs2243093 (C) p = 0.2991 p = 0.005 –
TBX5 rs1895602 (T) p = 0.352 p = 0.003 –
AGTR1 rs33978228 (G) p = 0.0196 – –
rs427832 (G) p = 0.2177 p = 0.005 –
IHH rs3099 (C) p = 0.1565 p = 0.003 –
EPAS1 rs1867785 (G) p = 0.958 p = 0.001 –
aCases/controls.
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(CXCR4), HIF1A signaling and angiogenesis (ANGPT2, H2AFX, 
and VEGF), and developmental processes (TGFb1, IHH) observed 
in the present study (Table 1), confirms the involvement of genes 
in ROP pathogenesis. A previous study reported the association 
of polymorphisms in IHH, AGTR1, TBX5, CETP, GP1BA, EPAS1, 
BDNF, and CFH with ROP (11, 13). However, only a few of these 
associated variants could be replicated in the present cohort, 
indicating allelic heterogeneity (Table  3). Thus, the novel and 
associated variants identified in the present study (Tables 1 and 
3) and elsewhere should be screened across multiple populations 
to understand their implications in ROP.
The strong associations of CFH, CFB, and C3 variants in our 
ROP patients along with elevated levels of C3 and CFH proteins 
in their vitreous (Table 1 and Figure 1A) indicated a possible 
involvement of the alternative complement pathway in ROP. 
CFH and CFB are the regulators of the alternative comple-
ment immune pathway (30). Upon activation, CFB is cleaved 
by complement factor D yielding two subunits, Ba and Bb. The 
active subunit Bb associates with C3b to form C3 convertase of 
alternative pathway while CFH regulates the alternative pathway 
activation by accelerating the decay of C3 convertase (30). It was 
also noted that there was an increase in the formation of CFB in 
oxygen induced retinopathy (OIR) mice model (31). Thus, the 
observed genetic associations of CFH and CFB complemented 
with their increased expression of cleaved C3 protein fragments 
in the vitreous of ROP-affected eyes in our study confirmed 
their possible involvement in disease pathogenesis (Figure  5). 
Generally, complement factors are known to be downregulated in 
the normal preterm neonates because of immature development 
of the immune system (32, 33). On the contrary, we observed 
an elevation and activation of the complement components and 
complement factors in the vitreous of ROP patients at infancy 
(Figure  1), suggesting an important role of the complement 
pathway in ROP pathogenesis.
Interestingly, the genetic variants in CFH, C3, and CFB genes 
have also been associated with AMD susceptibility (34, 35). 
A Y402H variant in the CFH gene was found to be most strongly 
associated with AMD patients worldwide. However, the ROP-
associated CFH variant (rs374896) identified in the present study 
is located in the intron of the gene (Table 1). Further, functional 
studies on CFH in AMD eyes have shown that chronic low grade 
intraocular complement activation in patients carrying the risk 
variants in CFH along with exposure to environmental triggers 
(smoking, oxidative stress, etc.) causes the retinal pigment epithe-
lial damage leading to neurodegeneration and neovascularization 
and eventually visual loss (36).
Complement components do not mediate neovascularization 
by itself but via the inflammatory cells (37). As was demonstrated 
in an OIR mouse model, complement factors C3a and C5a activate 
macrophages by binding to C3aR and C5aR, thereby regulating 
angiogenesis (38). In the present study, a strong association 
(p = 1.32 × 10−8) of rs2228014 in CXCR4 (Table 1) along with 
the presence of activated microglia/macrophages in the vitreous 
FigUre 5 | Schematic diagram of the proposed mechanism of complement activation and its potential effect on macrophage-mediated angiogenesis in retinopathy 
of prematurity. Cleavage of complement components C3 into C3a, C3b and further into iC3b, C3dg and C3cα; C4 into C4a and C4b and C5 into C5a and C5b 
leading to the activation of complement cascade, which in turn activates macrophage/microglia or vice versa. Activated macrophage/microglia secretes MMPs, 
cytokines, proangiogenic proteins, and reduced angiogenesis inhibitors that may lead to increased vessel proliferation and extracellular matrix (ECM) degradation in 
turn promoting angiogenesis. Red bars represent upregulation of the complement components observed in the present study.
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(Figure  1C), implicate their role in ROP angiogenesis via the 
leukocyte transendothelial migration. CXCR4 is a chemokine 
receptor for stromal derived factor 1 (CXCL12/SDF-1), 
which is mainly involved in the extravasation and migration 
of lymphocytes and monocytes (39). Inhibition of CXCR4 has 
been shown to result in reduced vascular sprouting following 
VEGF treatment in retinal explants (40). Our observation of the 
association of variants in VEGF, ANGPT2, and H2AFX (Table 1) 
indicate the involvement of HIF1α signaling pathway (hypoxia) 
in ROP pathogenesis. Furthermore, the secretion of C3 and 
VEGF by microglial cells under hypoxia (Figure  2) validated 
that hypoxia induced microglia/macrophage along with the 
complement component, could be contributing to the neovas-
cularization in ROP eyes. The high level of α2-macroglobulin 
in the ROP vitreous (Figure  3A) also indicated the presence 
of activated macrophages/microglia that further interacts with 
low-density lipoprotein receptor-related protein 1 (LRP1) which 
in turn induces MMP9 expression (41, 42).
Based on published studies on macrophages/microglia activa-
tion leading to inflammation (37), we proposed that increased 
expression of the complement components, VEGF, other 
cytokines, and ECM components (MMPs) in the vitreous of 
ROP patients are mediated by macrophage/microglia activation 
by creating an imbalance of angiogenic and anti-angiogenic mol-
ecules (Figure 5). The proteolytic degradation of ECM is a critical 
step for the invasion of blood vessels during neovascularization. 
MMPs are endoproteases that cleaves the protein components of 
the ECM while TIMPs, α2 macroglobulins, and α1 antitrypsin 
are the proteinase inhibitors (43). In proliferative diabetic retin-
opathy, the elevated levels of MMP-2 and MMP-9 were shown to 
cause ECM remodeling (44, 45) further leading to net collagen 
IV degradation and vitreous liquefaction (46). The presence 
of activated MMP-9 in the vitreous along with elevated levels 
of TIMP1, TIMP2, and α2 macroglobulin in our ROP patients 
and presence of blood component proteins like apolipoproteins 
(Figures  1A and 3A) explained its role in the degradation of 
the basement membrane of blood vessels, seeping out into the 
vitreous along with the other blood components, thereby causing 
vitreous hemorrhage and vitreous liquefaction.
Presence of inflammatory markers in the vitreous or other body 
fluid in young preterm babies might suggest an infectious etiology 
and inflammatory stimuli contributing to ROP (47). Fetal inflam-
matory response syndrome (including sepsis, periventricular 
leukomalacia, intraventricular hemorrhage, necrotizing entero-
colitis, and bronchopulmonary dysplasia), chorioamnionitis, 
and microbial infections are some of the predisposing factors for 
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inflammation observed in some studies (48). There was no evi-
dence of exposure to infection in our cohort since babies with any 
microbial infections were excluded. Additionally, we did not find 
any difference in the complement levels or activation patterns in 
the serum of these patients and controls unlike in the vitreous sam-
ples, further ruling out any systemic infection (data not shown). 
Based on these evidences, neonatal non-infectious inflammation 
might be playing a major role in the pathogenesis of ROP.
Based on these findings supplemented with increasing evi-
dences on the role of inflammation in causing neovascularization, 
we speculated if MMPs could be detected in the tear samples of 
ROP babies so that it could be used as markers for ROP progres-
sion. The tear samples were an obvious choice for this study as it 
is fairly non-invasive, safe, and convenient, although there were 
some restrictions of tear volume and sampling in the ROP babies. 
It was interesting to note that the levels of MMPs in tears were 
significantly higher in severe ROP compared to no-ROP and 
mild ROP eyes that underscored its potential use as a biomarker 
for an early prediction of this condition (Figures 3E and 4). This 
was further confirmed by zymography, with an increasing trend 
of the activated MMPs (both 2 and 9) in all the samples of severe 
stages of ROP along with a case of mild ROP. This mild ROP baby 
eventually progressed very quickly to a severe stage (plus ROP) 
in 2  weeks and did not respond to laser therapy (Figure  3E). 
The subsequent validation of these initial findings was done in 
an extended cohort and the increased levels of MMPs with the 
increase in severity of disease further established the usefulness 
of MMPs in tears as potential biomarkers. While our data proved 
that the levels of MMPs could reliably predict the progression of 
ROP (Figure 4), we could not perform any longitudinal analysis 
of MMPs levels in the tears due to the difficulties in obtaining 
samples from preterm babies at regular intervals. Likewise, 
a direct correlation of genotypes with protein levels or their 
activities in the corresponding biological material (vitreous/
aqueous/tear) and clinical phenotype could not be attempted. 
Nevertheless, our study provided a proof of concept that tear 
MMPs levels could be a potential predictor for ROP progression 
in preterm babies.
In conclusion, the assessment of the activation of alternate 
complement pathway in ROP based on the novel genetic associa-
tions indicated the possible mechanisms of immune activation that 
could lead to aberrant neovascularization in the retina. However, 
the detailed underlying mechanisms of immune activation in 
abnormal blood vessel proliferation and neurodegeneration in 
the early stages of ROP are yet to be understood. Additionally, our 
results emphasized the primary role of complement component 
C3 in abnormal angiogenesis as seen in proliferative ROP. The 
proteins involved in the alternative complement pathway could 
be targeted selectively to prevent neovascularization, which 
might be helpful in preventing vision loss due the progression 
of ROP. The association of ECM-related genes with ROP along 
with elevated levels of the corresponding ECM proteins and its 
activation in the vitreous of ROP patients suggested its possible 
role in blood-retinal barrier degradation, which could promote 
neovascularization. Finally, the elevated levels of MMPs in tears 
of ROP patients established its role as a potential biomarker for 
the prediction of progression to proliferative stages. However, 
this needs to be replicated in other extended cohorts worldwide 
using a longitudinal study design. The present treatment strate-
gies for managing severe ROP are inefficient as they target only 
the later vasoproliferative phase of ROP. Diagnosing and treating 
the disease at an earlier stage would definitely help in the timely 
and efficient management of this disease. The results of this study 
would aid in finding biomarkers for predictive testing as well as 
identifying newer drug targets for an efficient management of 
ROP.
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